A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
NSCLC (Non-small Cell Lung Cancer)
DRUG: Cadonilimab (AK104)|DRUG: Sugemalimab
Progression-free survival (PFS) assessed by INV, PFS is defined as the time from randomization until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1)., 3 years
OS, Time from randomization to death, 5 years|6-month PFS rate assessed by INV, PFS rate at 6 months, 3 years|AEs, Adverse events incidence and severity, clinically significant abnormal laboratory test results., 3 years
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.